Literature DB >> 2778565

Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis.

C Maurage1, C Lenaerts, A Weber, P Brochu, I Yousef, C C Roy.   

Abstract

Although dehydrated obstructing mucus is thought to account for the obstructive pathology involving the lungs, the pancreas, the reproductive system, and the intestinal tract, its relationship with CF-associated liver disease remains largely hypothetical and little is known about possible risk factors. Complete clinical and autopsy records were available in 38 of 73 deaths occurring over a 10-year period. The liver was normal in only five cases, and they were all infants. Steatosis was the only lesion present in 9, hypoxic liver disease was documented in 8, and biliary cirrhosis in 16 (focal in 10 and multilobular in 6). There was no relationship between the presence of cirrhosis, gallbladder abnormalities, age at death, and clinical status recorded during the year precoding their demise. Mucus plugs characterized by amorphous eosinophilic material within proliferated bile ductules were present in 75% of children with focal or multilobular biliary cirrhosis as opposed to 14% in those without (p = 0.015). A history of meconium ileus or its equivalent was recorded more frequently (p = 0.038) in those with cirrhosis. Finally, biliary cirrhosis was invariably present when there was a history of meconium ileus or its equivalent and when mucus plugs were noted. These findings suggest that patients with intestinal obstruction are at greater risk for the development of cirrhosis and that strategies should be developed to increase the detergent capacity of bile and its flow in order to decrease the viscosity of mucus in the biliary tree.

Entities:  

Mesh:

Year:  1989        PMID: 2778565

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  9 in total

1.  Prevalence of liver disease in cystic fibrosis.

Authors:  R Scott-Jupp; M Lama; M S Tanner
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

2.  Liver and biliary problems in cystic fibrosis.

Authors:  M S Tanner
Journal:  J R Soc Med       Date:  1992       Impact factor: 5.344

Review 3.  Liver disease in cystic fibrosis.

Authors:  M S Tanner; C J Taylor
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

Review 4.  Oral bile acids in cystic fibrosis-associated liver disease.

Authors:  C Colombo; A Crosignani; M G Apostolo; M T Marzano; N Bettinardi; A Giunta
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

5.  Hypoglycaemia and Golytely in distal intestinal obstruction syndrome.

Authors:  A Shah; S Madge; R Dinwiddie; P Habibi
Journal:  J R Soc Med       Date:  1994-02       Impact factor: 5.344

6.  Retrospective review of cystic fibrosis presenting as infantile liver disease.

Authors:  R Shapira; N Hadzic; R Francavilla; G Koukulis; J F Price; G Mieli-Vergani
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

7.  Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis.

Authors:  Scott M Blackman; Rebecca Deering-Brose; Rita McWilliams; Kathleen Naughton; Barbara Coleman; Teresa Lai; Marilyn Algire; Suzanne Beck; Julie Hoover-Fong; Ada Hamosh; M Daniele Fallin; Kristen West; Dan E Arking; Aravinda Chakravarti; David J Cutler; Garry R Cutting
Journal:  Gastroenterology       Date:  2006-07-24       Impact factor: 22.682

8.  Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

Authors:  J Feigelson; C Anagnostopoulos; M Poquet; Y Pecau; A Munck; J Navarro
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

9.  Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases.

Authors:  Sophie Collardeau-Frachon; Raymonde Bouvier; Catherine Le Gall; Christine Rivet; Faiza Cabet; Gabriel Bellon; Alain Lachaux; Jean-Yves Scoazec
Journal:  Virchows Arch       Date:  2007-06-07       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.